Radicle Energy: A Study Assessing the Impact of Health and Wellness Products on Fatigue

Launched by RADICLE SCIENCE · May 22, 2025

Keywords

ClinConnect Summary

The Radicle Energy study is looking into how certain health and wellness products can help reduce fatigue and improve overall health. This clinical trial will be conducted in a fair way, meaning that some participants will receive the actual product while others will receive a placebo (a product without active ingredients) without knowing which one they have. The study is set to start soon and is open to adults aged 21 and older from all backgrounds living in the United States who are willing to try the product and have the potential for significant improvement in their fatigue.

To participate, individuals should be generally healthy, not pregnant or breastfeeding, and should not be enrolled in another clinical trial. Participants will need to have reliable internet access and must not have certain health conditions that could make it unsafe for them to use the study products. Throughout the trial, participants can expect to track their fatigue levels and related health outcomes, helping researchers understand how these wellness products might make a difference in people's lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities
• • o Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed
• • Resides in the United States
• • Has the opportunity for at least 30% improvement in their primary health outcome
• • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
• Exclusion Criteria:
• • Report being pregnant, trying to become pregnant, or breastfeeding
• • Unable to provide a valid US shipping address and mobile phone number
• • Reports current enrollment in another clinical trial
• • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
• • Unable to read and understand English
• • Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
• • Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.
• • o NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
• • Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.
• • o Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products
• • Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products and/or pose a safety risk
• • Lack of reliable daily access to the internet